Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Blood Adv. 2024 Aug 13;8(15):3875-3879. doi: 10.1182/bloodadvances.2024013212.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1* / antagonists & inhibitors
  • ADP-ribosyl Cyclase 1* / metabolism
  • Aged
  • Aged, 80 and over
  • Antibodies, Bispecific / therapeutic use
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • CD28 Antigens
  • CD3 Complex / immunology
  • Female
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Male
  • Membrane Glycoproteins
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism

Substances

  • ADP-ribosyl Cyclase 1
  • Antibodies, Monoclonal, Humanized
  • isatuximab
  • CD3 Complex
  • CD28 Antigens
  • Antibodies, Bispecific
  • CD38 protein, human
  • Membrane Glycoproteins